Related Experiment Video
Updated: Apr 10, 2026
07:59
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.9K
The Perfect Pathology Report After Neoadjuvant Therapy.
Caterina Marchiò1, Francesca Maletta1, Laura Annaratone1
1Department of Medical Sciences, University of Turin, Turin, Italy (CM, FM, LA, AS).
Journal of the National Cancer Institute. Monographs
|June 12, 2015
Summary
Accurate breast cancer neoadjuvant therapy response assessment relies on precise pathology reporting. This review highlights critical issues and offers a pragmatic approach for optimal histopathological evaluation of residual disease.
Area of Science:
- Oncology
- Pathology
- Medical Diagnostics
Background:
- Neoadjuvant therapy is crucial for breast cancer management.
- Accurate assessment of therapy response requires meticulous specimen handling and detailed histological reporting.
- Current guidelines for specimen handling and reporting in this context are minimal, leading to incomplete pathology reports.
Purpose of the Study:
- To analyze critical issues in histopathological assessment of neoadjuvant therapy response in breast cancer.
- To provide a pragmatic approach for generating comprehensive and accurate pathology reports.
- To improve the evaluation of residual disease and therapy response for better patient management.
Main Methods:
- Review of current practices and challenges in histopathological specimen handling and reporting.
- Analysis of the American Joint Committee on Cancer (AJCC) staging classification for post-treatment residual disease (ypT).
- Discussion of essential components for comprehensive histopathological reports, including grossing, sectioning, and mandatory information.
Main Results:
- Pathology reports often lack crucial parameters for assessing therapy response.
- Pathologists require clinical and radiological information for accurate grossing and assessment.
- Comprehensive mapping and large sections are vital for determining disease extent, especially for impalpable lesions.
- Reports must include histotyping, staging (ypTNM), prognostic/predictive factors, and response categorization.
Conclusions:
- Standardized and comprehensive histopathological reporting is essential for evaluating neoadjuvant therapy response in breast cancer.
- A pragmatic approach is needed to ensure all critical information is included in pathology reports.
- Improved pathology reporting will enhance the multidisciplinary management of breast cancer patients.
